GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Diplomat Pharmacy Inc (NYSE:DPLO) » Definitions » Return-on-Tangible-Asset

Diplomat Pharmacy (Diplomat Pharmacy) Return-on-Tangible-Asset : -117.09% (As of Sep. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Diplomat Pharmacy Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Diplomat Pharmacy's annualized Net Income for the quarter that ended in Sep. 2019 was $-709 Mil. Diplomat Pharmacy's average total tangible assets for the quarter that ended in Sep. 2019 was $606 Mil. Therefore, Diplomat Pharmacy's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2019 was -117.09%.

The historical rank and industry rank for Diplomat Pharmacy's Return-on-Tangible-Asset or its related term are showing as below:

DPLO's Return-on-Tangible-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.83
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Diplomat Pharmacy Return-on-Tangible-Asset Historical Data

The historical data trend for Diplomat Pharmacy's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diplomat Pharmacy Return-on-Tangible-Asset Chart

Diplomat Pharmacy Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Return-on-Tangible-Asset
Get a 7-Day Free Trial 1.89 6.51 5.57 2.56 -47.43

Diplomat Pharmacy Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 -200.18 -9.73 -107.60 -117.09

Competitive Comparison of Diplomat Pharmacy's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Diplomat Pharmacy's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diplomat Pharmacy's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Diplomat Pharmacy's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Diplomat Pharmacy's Return-on-Tangible-Asset falls into.



Diplomat Pharmacy Return-on-Tangible-Asset Calculation

Diplomat Pharmacy's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2018 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=-302.269/( (679.268+595.451)/ 2 )
=-302.269/637.3595
=-47.43 %

Diplomat Pharmacy's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2019 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2019 )  (Q: Jun. 2019 )(Q: Sep. 2019 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2019 )  (Q: Jun. 2019 )(Q: Sep. 2019 )
=-709.12/( (604.92+606.337)/ 2 )
=-709.12/605.6285
=-117.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2019) net income data.


Diplomat Pharmacy  (NYSE:DPLO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Diplomat Pharmacy Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Diplomat Pharmacy's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Diplomat Pharmacy (Diplomat Pharmacy) Business Description

Traded in Other Exchanges
N/A
Address
4100 South Saginaw Street, Flint, MI, USA, 48507
Diplomat Pharmacy Inc. is active in the U.S. healthcare sector. It provides specialty pharmacy and infusion services, including pharmacy solutions for chronic diseases. The company has two main segments: specialty pharmacy and pharmacy benefit management. Its specialty pharmacy segment offers solutions to dispense, deliver, and dose prescription drugs. The pharmacy benefit management segment offers services to help control pharmacy benefit dollars and maximize quality of care. It derives most of its revenue through prescription drug sales in the United States.
Executives
Brian T Griffin director, officer: Chairman and CEO
David C Dreyer director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Regina M. Benjamin director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Benjamin Wolin director C/O EVERYDAY HEALTH, INC., 345 HUDSON STREET, 16TH FLOOR, NEW YORK NY 10014
Jeffrey G Park director C/O DIPLOMAT PHARMACY, INC., 4100 S. SAGINAW ST., FLINT MI 48507
Sean Whelan director, officer: Chief Financial Officer C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Jeffrey M Rowe director, officer: EVP of Operations C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018

Diplomat Pharmacy (Diplomat Pharmacy) Headlines

From GuruFocus

Diplomat Appoints Dave Loschinskey as Chief Operating Officer

By PRNewswire PRNewswire 05-07-2019

Diplomat Using SMRxT Technology to Enhance Patient Care

By PRNewswire PRNewswire 04-26-2019